Laura Ahola

Medical Devices

MSc in Neuroscience & Physiology, Biology

Laura Ahola

Laura Ahola works at Measurlabs as a medical device testing expert, specializing in sterility, toxicity, and biocompatibility testing. She has experience coordinating customer projects to meet both EU MDR and FDA 510(k) requirements.

Laura holds an MSc in neuroscience & physiology from the University of Helsinki, and she has also qualified and worked as a biology teacher before joining Measurlabs. 

Articles in other media

Laura has authored the following articles for medical industry publications: 

Laura’s latest articles in our blog

Read articles by our experts and guest authors on the practical implications of regulations, scientific advancements, and the ideal uses of different analysis methods.

Laura’s top testing services

Neutral red uptake (NRU) assay for cytotoxicity assessment

ISO 10993-5
The NRU assay is a quantitative test to determine the potential biological reactivity of a mammalian cell culture in response to a medical device extract. It is described in Annex A of ISO 10993-5 and is one of the most commonly used methods for medical device cytotoxicity testing. The test item is extracted in cell culture medium, which is suitable for both polar and non-polar extracts. The cells are exposed to the extract, and their viability is assessed after staining with neutral red (NR) solution. The number of viable cells correlates with the color intensity determined by photometric measurements, as non-viable cells do not absorb NR. The medical device is considered non-cytotoxic if the percentage of viable cells is ≥ 70 % of the untreated control.
860 €
Read more

Face mask tests according to EN 14683 for type II and type IIR masks

EN 14683, ISO 10993-10, ISO 10993-5, …
We offer comprehensive test packages for verifying the quality of type II and type IIR face masks according to the EN 14683 standard. The tests included in the packages are required to label face masks with the CE marking. Medical face masks are divided into Types I and II according to their bacterial filtration efficiency. Type I masks are not intended for healthcare professionals, but for the public to prevent the spread of infectious diseases. Type II masks are further classified based on whether they are splash-resistant (Type IIR) or not (Type II). To comply with the European Standard EN 14683, Type II face masks must undergo the following quality tests: Bacterial filtration efficiency (BFE) - The ability of the face mask to filter the bacterium Staphylococcus aureus. The BFE is expressed as the percentage of colony-forming units (cfu) that have passed via aerosol through the facemask. If a face mask consists of two or more areas with different characteristics, these areas will be tested separately., Breathability (Differential pressure) - The amount of differential pressure required to draw air through a measured surface area at a constant flow rate., Microbial cleanliness (Bioburden) - The measurement of colony forming units per gram as per EN ISO 11737-1., Biocompatibility - The medical face mask manufacturer shall complete a biocompatibility evaluation according to ISO 10993-1 as a surface device with limited contact. The applicable toxicology testing regimen shall also be determined.. In addition to the above, Type IIR masks require the following test: Splash resistance - Performed according to ISO 22609, this test determines the ability of a face mask to resist penetration of splashes of liquid at different pressures.. The lower displayed price applies to the Type II mask test package, while the higher price also includes the splash resistance test required for Type IIR masks.
3,809–4,245 €
Read more

Microbiological analysis of pharmaceuticals & cosmetics according to European Pharmacopoeia

Ph. Eur. 2.6.12., Ph. Eur. 2.6.13.
Microbiological test package for pharmaceutical or cosmetic products and ingredients according to European Pharmacopoeia methods Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13. The most recent edition of the pharmacopoeia is followed. The following parameters can be included in the analysis package: Total aerobic microbial count (TAMC) according to Ph. Eur. 2.6.12, Total combined yeasts and moulds count (TYMC) according to Ph. Eur. 2.6.12, Tests for specified microorganisms according to Ph. Eur. 2.6.13, including e.g., S. aureus, P. aeruginosa, E. coli, and C. albicans. These analyses are commonly conducted on the finished product and/or starting materials and intermediates as part of pharmaceutical batch release testing.
105 €
Read more

Bacterial reverse mutation test (AMES) for genotoxicity evaluation

ISO 10993-3, ISO 10993-33, OECD 471
The bacterial reverse mutation (AMES) test is used to evaluate the genotoxic effect of a medical device or its extract when in contact with a bacterial suspension. The test is conducted according to OECD 471 and ISO 10993-3 by exposing a bacterial suspension of Salmonella spp and Escherichia coli to 5 concentrations of the medical device or its pure extracts. The AMES test is a preliminary "screening test" for genotoxicity. A full genotoxicity evaluation usually includes testing the device with two in vitro methods, of which AMES is typically performed first. An additional in vivo method can be used if needed. Measurlabs can support you with the full genotoxicity evaluation. Please contact our experts for a quote.
2,810 €
Read more

Measurlabs offers 2000+ tests from 900+ laboratories.